Eps Corp operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Eps Corp with three other
miscellaneous service companies in Asia:
Chabiotech Co Ltd
of South Korea
sales of 449.26 billion Korean Won [US$401.64 million]
Hutchison China Meditech Limited
(1.44 billion Chinese Renmimbi [US$208.72 million]
of which 69%
was Drugs PRC), and
Takara Bio Inc
(29.73 billion Japanese Yen [US$267.26 million]
of which 92%
was Bio support).
Eps Corp reported sales of ¥52.70 billion (US$473.80 million)
September of 2016.
increase of 16.6%
versus 2015, when the company's sales were ¥45.20 billion.
Sales at Eps Corp have increased during each of the previous five years
(and since 2011, sales have increased a total of 64%).
Sales of Domestic Smo Business saw an increase
that was more than double the company's growth rate: sales were up
68.6% in 2016, from
¥6.45 billion to ¥10.87 billion.
Eps Corp also saw significant increases in sales in
Global Research Business (up 47.1% to ¥4.01 billion)
Others (up 58.8% to ¥1.49 billion)
Not all segments of Eps Corp experienced an increase in sales in 2016:
sales of Eps Business fell 7.4% to ¥3.94 billion.